Skip to main content
Full access
Government News
Published Online: 20 July 2001

Psychotropics on the FDA’s Priority Testing List (Drug/Indication)

alprazolam/anxiety
amphetamine/ADHD
bupropion/depression
buspirone/anxiety
citalopram/depression
clomipramine/OCD
clozapine/psychotic disorders
divalproex/mania
fluoxetine/OCD and depression
lorazepam/anxiety
methylphenidate/ADHD
mirtazepine/depression
modafanil/ADHD
naltrexone/substance abuse
nefazodone/depression
olanzapine/psychotic disorders
oxazepam/anxiety
paroxetine/OCD and depression
pemoline/ADHD
quetiapine/psychotic disorders
risperidone/psychotic disorders
sertraline/OCD and depression
trazodone/depression
valproate/mania
venlafaxine/GAD and depression
Source: FDA; Center for Drug Evaluation and Research, December 2000

Information & Authors

Information

Published In

History

Published online: 20 July 2001
Published in print: July 20, 2001

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share